Patent SG-11201407802W-A (SG)
Title: Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
Inventor: GALETTO ROMAN
IPC: A61K35/17
Filed: 2013-05-13
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 November 2013 (28.11.2013) WIPOIPCT (10) International Publication Number WO 2013/176915 A1 (51) International Patent Classification: C12N 5/0783 (2010.01) (21) International Application Number: PCT/US2013/040755 (22) International Filing Date: 13 May 2013 (13.05.2013) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 61/651,933 25 May 2012 (25.05.2012) US 61/696,612 4 September 2012 (04.09.2012) US (72) Inventors; and (71) Applicants GALETTO, Roman : [IT/FR]; 18, Rue Com- mines, F-75003 Paris (FR). GOUBLE, Agnes [FR/FR]; 65 Rue De Tocqueville, F-75017 Paris (FR). GROSSE, Stephanie [FR/FR]; 7 Moras, F-77750 Saint-cyr Sur Mor- in (FR). MANNIOUI, Cecile [FR/FR]; 8 Bis Rue Maurice Roy, F-94350 Villiers Sur Marne (FR). POIROT, Laurent [FR/FR]; 4 Rue De Torcy, F-75018 Paris (FR). SCHARENBERG, Andrew [US/US]; 1222, NW Nor- cross Way, Seattle, WA 98177 (US). SMITH, Julianne [US/FR]; 13, Rue de la Ferme, F-92350 Le Plessis Robin­ son (FR). (74) Agent: SHIER, Vincent, K.; Obion, Spivak, McClelland, Maier & Neustadt, L.L.P, 1940 Duke Street, Alexandria, VA 22314 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) [Continued on next page] (54) Title: METHODS FOR ENGINEERING ALLOGENEIC AND IMMUNOSUPPRESSIVE RESISTANT T CELL FOR IM­ MUNOTHERAPY •H 0\ l> i-H o CJ (57) Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immun­ osuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such poly­ peptides, to precisely target selection of a key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections. WO 2013/176915 A11 lllll llllllll II llllll III lllll lllll III III III lllll llll llll lllll lllll lllll lllll lllllll llll llll — with sequence listing part of description (Rule 5.2(a))